Tape preparation of WT1 peptide cancer vaccine for transdermal administration

Patent metadata

Field	Value
Publication number	US-10195258-B2
Application number	US-201414166954-A
Country	US
Kind code	B2
Filing date	Jan 29, 2014
Priority date	Feb 5, 2013
Publication date	Feb 5, 2019
Grant date	Feb 5, 2019

Abstract

The present invention provides a cancer vaccine tape preparation for inducing cellular immunity, comprising:
a support, an adhesive layer comprising an adhesive disposed on one side of the support, wherein the adhesive layer carries a combination of: (i) a WT1 peptide and/or a modified WT1 peptide; and (ii) a first cellular immunity induction promoter. The tape preparation can provides high efficacy.

First claim

What is claimed is:

1. A method for inducing cellular immunity in a subject, which comprises applying a cancer vaccine tape preparation, comprising:
a support, and
an adhesive layer comprising an adhesive disposed on one side of the support, wherein the adhesive layer carries a combination of:
(i) a WT1 peptide and/or a modified WT1 peptide;
(ii) imiquimod;
(iii) at least one helper peptide and/or modified helper peptide; and
(iv) myristic acid,

to the skin of the subject under a mildly irritating condition.

2. The method according to claim 1 , wherein the method is for treating a cancer in the subject.

3. The method according to claim 1 , wherein the adhesive of the tape preparation is an acrylic adhesive.

4. The method according to claim 1 , wherein the adhesive of the tape preparation is a rubber-based adhesive.

5. The method according to claim 4 , wherein the rubber-based adhesive is polyisobutylene rubber adhesive.

6. The method according to claim 1 , wherein the adhesive of the tape preparation is a silicone-based adhesive.

7. The method according to claim 1 , wherein the adhesive layer further carries a skin permeability enhancer.

8. The method according to claim 1 , wherein the mildly irritating condition is a condition under which transepidermal water loss (TEWL) in a model animal for skin irritation evaluation before the administration of the composition is 50 g/h·m 2 or less.

9. The method according to claim 1 , wherein the mildly irritating condition is a condition under which the cutaneous TSLP level in a model animal for skin irritation evaluation at completion of the administration of the composition is 10000 pg/mg protein or less.

10. The method according to claim 1 , wherein the helper peptide is at least tubercle bacillus-derived helper peptide, measles virus-derived helper peptide, hepatitis B virus-derived helper peptide, hepatitis C virus-derived helper peptide, Chlamydia trachomatis -derived helper peptide, Plasmodium falciparum sporozoite-derived helper peptide, keyhole limpet haemocyanin-derived helper peptide, tetanus toxin-derived helper peptide, universal helper analog or cancer cell-derived helper peptide, excepting a WT1-derived helper peptide.

11. The method according to claim 1 , wherein the cancer vaccine tape preparation also comprises a cyclooxygenase inhibitor.

12. The method according to claim 1 , wherein the helper peptide is hWT1 35 helper peptide, hWT1 86 helper peptide, or hWT1 294 helper peptide.

13. A cancer vaccine tape preparation for use in the induction of cellular immunity, comprising:
a support, and
an adhesive layer comprising an adhesive disposed on one side of the support, wherein the adhesive layer carries a combination of:
(i) a WT1 peptide and/or a modified WT1 peptide;
(ii) imiquimod;
(iii) at least one helper peptide and/or modified helper peptide; and
(iv) myristic acid,

wherein the tape preparation is structurally configured and arranged for application to the skin of a subject.

14. The cancer vaccine tape preparation for use in the induction of cellular immunity according to claim 13 , wherein the helper peptide is at least tubercle bacillus-derived helper peptide, measles virus-derived helper peptide, hepatitis B virus-derived helper peptide, hepatitis C virus-derived helper peptide, Chlamydia trachomatis -derived helper peptide, Plasmodium falciparum sporozoite-derived helper peptide, keyhole limpet haemocyanin-derived helper peptide, tetanus toxin-derived helper peptide, universal helper analog or cancer cell-derived helper peptide, excepting a WT1-derived helper peptide.

15. The cancer vaccine tape preparation for use in the induction of cellular immunity according to claim 13 , wherein the adhesive layer also carries a cyclooxygenase inhibitor.

Assignees

• Nitto Denko Corp
• Univ Osaka

Inventors

• Maeda Yoshiki
• Okubo Katsuyuki
• Asari Daisuke
• Okazaki Arimichi
• Shishido takuya
• Hori Mitsuhiko
• Sugiyama Haruo

Classifications

• A61K2039/80

  Vaccine for a specifically defined cancer · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/04

  Immunostimulants · CPC title

• A61K47/32

  Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone} · CPC title

• A61K39/39

  characterised by the immunostimulating additives, e.g. chemical adjuvants · CPC title